TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20723301

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus dipyridamole (100 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Simple chemotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (15 healthy individuals)
Number of subjects: 32
Study: 18305947

Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15877873

Group type: EXPERIMENTAL
Intervention: Carbonated mineral water (1 litre daily for 8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control mineral water (1 litre daily for 8 weeks)
Number of subjects: 18
Study: 12823129

Group type: EXPERIMENTAL
Intervention: FA-specific IgE detected in asthmatic children
Number of subjects: 155

Group type: COMPARATOR
Intervention: Nonallergic children
Number of subjects: 155
Study: 11961334

Group type: EXPERIMENTAL
Intervention: Original blackcurrant drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Experimental blackcurrant drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 10546009

Group type: EXPERIMENTAL
Intervention: Endocrinologists
Number of subjects: 260

Group type: COMPARATOR
Intervention: Generalists
Number of subjects: 260
Study: 8649278

Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 20 mg/kg/12h
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 8 mg/kg/8h
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 13 mg/kg/8h
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 20 mg/kg/8h
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intramuscular quinine 8 mg/kg/8h
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous quinine 12.5 mg/kg in a slow infusion over 4 hours/12h
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: New rectal quinine formulation 12.8 mg/kg/8h quinine gluconate
Number of subjects: 66
Study: 2260567

Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 189
Study: 7426887

Group type: EXPERIMENTAL
Intervention: Rapid injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over ten seconds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over two minutes
Number of subjects: 0
Study: 6151828

Group type: EXPERIMENTAL
Intervention: Butofilolol (200 mg, administered 24 hours and 2 hours before the test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (double blind)
Number of subjects: 20
Study: 30231943

Group type: EXPERIMENTAL
Intervention: Treat-all strategy (decolonization bundle for all patients without S. aureus screening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test-and-treat strategy (decolonization bundle if S. aureus found, otherwise SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC - 2 disinfectant soap showers)
Number of subjects: 0
Study: 27465250

Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:400,000
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:200,000
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:100,000
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:50,000
Number of subjects: 25
Study: 24488610

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of Cyclosporin-A (2.5 mg/kg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (CsA) in higher-risk patients
Number of subjects: 78
Study: 23477118

Group type: EXPERIMENTAL
Intervention: No nasal packing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 66
Study: 19890345

Group type: EXPERIMENTAL
Intervention: Early treatment with inhaled nitric oxide (20 p.p.m. of iNO)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation with FiO2 1.0 (Control group)
Number of subjects: 56
Study: 18405786

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (75, 100, 150, or 200 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous fentanyl (75, 100, 150, or 200 microg)
Number of subjects: 24
Study: 15724848

Group type: EXPERIMENTAL
Intervention: New examination system (workload-capability model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old examination system (diagnosis-focused)
Number of subjects: 0
Study: 14674737

Group type: EXPERIMENTAL
Intervention: Intervention group (Healthy Directions study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10839333

Group type: EXPERIMENTAL
Intervention: Quetiapine (150 to 600 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quetiapine (single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 12
Study: 8676807

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) supplemented with ketoacids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-protein diet (LPD) without ketoacids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 12
Study: 1466184

Group type: EXPERIMENTAL
Intervention: 3% urea cream (HTH lotion 'light')
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 10% urea cream (HTH lotion 'Original')
Number of subjects: 47

Group type: COMPARATOR
Intervention: Untreated control (contralateral forearm)
Number of subjects: 47
Study: 6732409

Group type: EXPERIMENTAL
Intervention: Large adult cuff
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Thigh cuff
Number of subjects: 470

Group type: COMPARATOR
Intervention: Standard cuff
Number of subjects: 470
Study: 30811460

Group type: EXPERIMENTAL
Intervention: Training seminar for clinicians
Number of subjects: 178

Group type: COMPARATOR
Intervention: Post-seminar support and mentoring
Number of subjects: 178
Study: 29381650

Group type: EXPERIMENTAL
Intervention: HIIT (14 repeats of 20‐s swimming session with 10‐s pause between sessions, 4 d·wk for 6 wk)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: AT (treadmill running, 60 min at 30 m·min, 5 d·wk for 8 wk)
Number of subjects: 21

Group type: COMPARATOR
Intervention: CON (sedentary control)
Number of subjects: 21
Study: 26760604

Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 158

Group type: COMPARATOR
Intervention: Basket catheter
Number of subjects: 158
Study: 24470557

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) and temsirolimus (50 mg weekly, adjusted based on toxicities)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) and temsirolimus (maximum tolerated dosage of 15 mg weekly)
Number of subjects: 69
Study: 21717120

Group type: EXPERIMENTAL
Intervention: Arm-powered (AP) handcycling
Number of subjects: 12

Group type: COMPARATOR
Intervention: Arm-trunk-powered (ATP) handcycling
Number of subjects: 12
Study: 19913323

Group type: EXPERIMENTAL
Intervention: Viramidine 600 mg twice daily
Number of subjects: 962

Group type: COMPARATOR
Intervention: Ribavirin (1000 or 1200 mg/day based on weight)
Number of subjects: 962
Study: 17868354

Group type: EXPERIMENTAL
Intervention: True acupuncture (according to TCM) plus Rizatriptan
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ritualized mock acupuncture plus Rizatriptan
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Standard mock acupuncture plus Rizatriptan
Number of subjects: 160

Group type: COMPARATOR
Intervention: No prophylactic treatment with relief therapy only (Rizatriptan)
Number of subjects: 160
Study: 15507508

Group type: EXPERIMENTAL
Intervention: Calcium supplement (Ca-suppl.) of 850 mg/d
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Calcium supplement (Ca-suppl.)
Number of subjects: 144
Study: 12885714

Group type: EXPERIMENTAL
Intervention: Pathways study intervention for primary prevention of obesity
Number of subjects: 1704
Study: 11220353

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 365

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 365
Study: 8857857

Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet (IED) - Immun‐Aid, McGaw, Inc., Irvine, CA; n = 17
Number of subjects: 35

Group type: COMPARATOR
Intervention: Isonitrogenous, isocaloric diet - Promote (Ross Laboratories, Columbus, OH) and Casec (Mead‐Johnson Nutritionals, Evansville, IN); n = 18
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unfed controls; n = 19
Number of subjects: 35
Study: 1518261

Group type: EXPERIMENTAL
Intervention: Chemotherapy (9 different intensive chemotherapy regimens)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regular maintenance therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 39

Group type: COMPARATOR
Intervention: No therapy or palliative therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Transplantation in relapse
Number of subjects: 39
Study: 6222590

Group type: EXPERIMENTAL
Intervention: Hansson nail (less traumatizing cylindric nail)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Rydell nail (four-flanged nail)
Number of subjects: 82
Study: 29393147

Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fat-free milk
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 27306628

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg orally every week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 50
Study: 26205962

Group type: EXPERIMENTAL
Intervention: CRM team leader training (CRM-TL)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Additional ALS training (ALS add-on)
Number of subjects: 180
Study: 23803881

Group type: COMPARATOR
Intervention: High-glycemic index meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-glycemic index meal
Number of subjects: 12
Study: 21119130

Group type: EXPERIMENTAL
Intervention: Breeze Self-Adhesive Resin Cement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RelyX Unicem Self-Adhesive Universal Resin Cement
Number of subjects: 20

Group type: COMPARATOR
Intervention: RelyX ARC Adhesive Resin Cement
Number of subjects: 20
Study: 18925348

Group type: EXPERIMENTAL
Intervention: Aggression-prevention treatment (specific details not provided)
Number of subjects: 489
Study: 16897918

Group type: EXPERIMENTAL
Intervention: Computer administration of the CTS with increased minimum item display duration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hierarchical order presentation of CTS items
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interspersed order presentation of CTS items
Number of subjects: 0
Study: 12837139

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 10 mg/day)
Number of subjects: 84
Study: 10648297

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8888803

Group type: EXPERIMENTAL
Intervention: Carmofur (HCFU) for 1 year
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group receiving no HCFU
Number of subjects: 173
Study: 1913758

Group type: EXPERIMENTAL
Intervention: Thermal stimulation (alternating warm and cool immersion) at frequencies of 0.013‐0.096 Hz and stimulus amplitude exceeding 10 degrees C.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation (mean temperature of 23‐33 degrees C).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thermal stimulation of the sitting subjects' forearm instead of legs.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thermal stimulation and sham stimulation.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Local cooling of the stimulated lower legs.
Number of subjects: 18
Study: 6689091

Group type: EXPERIMENTAL
Intervention: 0.1 g of dazoxiben
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.25 g or 1.0 g of acetylsalicylic acid (ASA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30557128

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both IXEQ4W and IXEQ2W)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 363
Study: 30004001

Group type: EXPERIMENTAL
Intervention: Procera® crowns
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: IPS e.max Press crowns
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Crown therapy (both types)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 27
Study: 25017958

Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 120
Study: 23009873

Group type: COMPARATOR
Intervention: 500 mg oral ciprofloxacin twice daily for 1 day before and for 2 days after biopsy (group 1)
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous amikacin 30 minutes before biopsy plus 500 mg oral ciprofloxacin (group 2)
Number of subjects: 1197
Study: 21753203

Group type: EXPERIMENTAL
Intervention: SAB0.3 (0.03% sorbic acid blend)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: SAB1 (0.1% sorbic acid blend)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: SAB5 (0.5% sorbic acid blend)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: SAB0.2 (0.2% sorbic acid blend)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Negative control (not challenged and not treated)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Positive control (challenged and not treated)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 225
Study: 18647851

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 24
Study: 17365266

Group type: EXPERIMENTAL
Intervention: 0.5% dithranol lipogel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conventional cream containing 1.15% dithranol, 1.15% salicylic acid and 5.3% coal tar
Number of subjects: 20

Group type: COMPARATOR
Intervention: Liposomal base
Number of subjects: 20
Study: 15028558

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 990

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study: 11772135

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg plus pseudoephedrine SR 120 mg twice daily for 2 to 3 weeks
Number of subjects: 0
Study: 9551285

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0
Study: 8746927

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (150 mg/week for two weeks, 300 mg/week for two weeks, and 600 mg/week for two weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2183732

Group type: EXPERIMENTAL
Intervention: Oral clindamycin hydrochloride
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral cephalexin
Number of subjects: 56
Study: 342797

Group type: EXPERIMENTAL
Intervention: Combined use of strophanthin and glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isolated use of strophanthin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isolated use of glucagon
Number of subjects: 0
Study: 31767470

Group type: EXPERIMENTAL
Intervention: Accelerated CHARTWEL schedule
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: CHARTWEL
Number of subjects: 146
Study: 30685773

Group type: EXPERIMENTAL
Intervention: Living within 500 meters of high voltage power lines
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Living between 500-1000 meters of high voltage power lines
Number of subjects: 933

Group type: COMPARATOR
Intervention: Living more than 1000 meters away from high voltage power lines
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Living within 500 meters of high voltage power lines (adjusted for confounding factors)
Number of subjects: 933
Study: 26429571

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 supplementation (20,000 IU/week)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Patients on immunomodulatory therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy
Number of subjects: 68
Study: 23835139

Group type: EXPERIMENTAL
Intervention: Group psychoeducation over six sessions plus treatment as usual (TAU) (n=19)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (n=15)
Number of subjects: 34
Study: 21787048

Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS) training
Number of subjects: 84
Study: 19323939

Group type: EXPERIMENTAL
Intervention: DB ACL reconstruction
Number of subjects: 64

Group type: COMPARATOR
Intervention: SB ACL reconstruction
Number of subjects: 64
Study: 17060265

Group type: EXPERIMENTAL
Intervention: Sublingual atropine for 48 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 48 hours
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sublingual atropine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 14965832

Group type: EXPERIMENTAL
Intervention: Group A: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy given in 8-12 fractions completed in 18-27 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Group B: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy in 15-18 fractions within 20-25 days
Number of subjects: 67
Study: 11686867

Group type: EXPERIMENTAL
Intervention: Soluble recombinant IL-4 receptor (IL-4 antagonist)
Number of subjects: 0
Study: 9197292

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 73

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 73
Study: 1406473

Group type: EXPERIMENTAL
Intervention: Broviac-type 'life-cath' and Groshong-catheter
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Parenteral therapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Catheter removal due to end of therapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Catheter-related complications
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Occlusion of the lumen
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Explantation due to suspected catheter-related sepsis
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cumulative patency rate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cumulative rate of functioning catheters
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 160
Study: 4019266

Group type: EXPERIMENTAL
Intervention: Expression method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Shield method
Number of subjects: 30
Study: 30289365

Group type: EXPERIMENTAL
Intervention: Formocresol (FC, n=40)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Chloramphenicol-Tetracycline-Zinc Oxide-Eugenol (CTZ, n=40)
Number of subjects: 58
Study: 29169668

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Investigational arthroscopy only
Number of subjects: 313

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 313
Study: 26645538

Group type: EXPERIMENTAL
Intervention: NIRS monitoring with treatment guideline intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: No action taken on alarms
Number of subjects: 67
Study: 24974353

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 22378112

Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL) with riboflavin and UV irradiation
Number of subjects: 14
Study: 19427680

Group type: EXPERIMENTAL
Intervention: ADAMTS13 900V variant
Number of subjects: 560

Group type: COMPARATOR
Intervention: ADAMTS13 Q448E
Number of subjects: 560

Group type: COMPARATOR
Intervention: ADAMTS13 P618A
Number of subjects: 560
Study: 17963428

Group type: COMPARATOR
Intervention: Prulifloxacin 600 mg tablet administered 3 hours before surgery (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 3 days (Group C)
Number of subjects: 20
Study: 16225568

Group type: EXPERIMENTAL
Intervention: Atosiban (114.75 mg intravenous infusion) + Labetalol (100 mg orally twice daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Atosiban (114.75 mg intravenous infusion) + Betamethasone (12 mg intramuscular injection)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Atosiban (114.75 mg intravenous infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Labetalol (100 mg orally twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Betamethasone (12 mg intramuscular injection)
Number of subjects: 32
Study: 12698990

Group type: EXPERIMENTAL
Intervention: FMI (final market image) tablet formulation of oxcarbazepine
Number of subjects: 0
Study: 9698695

Group type: EXPERIMENTAL
Intervention: Annual numerical clinical targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: No targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (target and no-target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Setting of clinical targets
Number of subjects: 0
Study: 8657506

Group type: EXPERIMENTAL
Intervention: 100 U/kg rHuEPO biweekly
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 400 U/kg rHuEPO biweekly
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Iron supplementation 10 mg/kg/week intravenously
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no rHuEPO or iron)
Number of subjects: 19
Study: 2261043

Group type: EXPERIMENTAL
Intervention: 50-minute lecture on the value of the autopsy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no lecture)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Total group of housestaff
Number of subjects: 53
Study: 6994982

Group type: EXPERIMENTAL
Intervention: Imipramine (1 mg/kg for 3 weeks)
Number of subjects: 22